Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Exicure Stock Surge: Exicure, Inc. shares rose 49.3% to $2.39 in pre-market trading after entering debt-for-equity exchange agreements and regaining Nasdaq compliance.
Other Notable Movers: NuCana plc gained 94.4%, Dermata Therapeutics rose 73.4%, and several other stocks experienced significant gains or losses in pre-market trading, reflecting a volatile market.
Analyst Views on GH
Wall Street analysts forecast GH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 92.84 USD with a low forecast of 60.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 111.980
Low
60.00
Averages
92.84
High
130.00
Current: 111.980
Low
60.00
Averages
92.84
High
130.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
